Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting · NCT06960395 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | EGFR; EGFR Positive Solid Tumors; Solid Tumor Malignancies | Recruiting | Phase 1 | 2026-04-13 | NCT06960395 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vir Biotechnology, Inc. | 9 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Honor Health Research Institute | Scottsdale | United States | 3 |
| MD Anderson | Houston | United States | 56 |
| Princess Alexandra Hospital | Woolloongabba | Australia | 106 |
| Wollongong Hospital | Wollongong | Australia | 29 |